News

Article

FDA Releases Draft Guidance on Labeling Safety

FDA issues draft guidance to minimize medication errors.

FDA has released the second in a series of three guidance documents written to minimize medication errors. The draft guidance offers guidelines to help prescription drug and biologic product manufacturers minimize medication errors and focuses on safety aspects of the container label and carton labeling design. The guidance also provides recommendations for ensuring that crucial elements of a product’s container labels and carton labeling are designed to promote safe dispensing, administration, and use. 

The guidance applies to prescription drug products marketed under an approved new drug application (NDA) or abbreviated new drug application (ANDA); prescription drugs marketed without an approved NDA or ANDA; and biological products marketed under an approved biologics licensing application (BLA). This guidance does not apply to over-the-counter (OTC) drug products.

The first guidance in the series focuses on minimizing risks associated with drug product design and container closure systems. The third planned guidance will focus on best practices for the development and testing of proposed proprietary names to minimize risks associated with drug product nomenclature, such as proprietary names that look or sound like the name of another product (e.g., look-alike or sound-alike names).

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More